Prostate Brachytherapy UK & Ireland 11-12 June 2026

Abstracts Archive

UK & Ireland Prostate Brachytherapy Conference 2019

Abstract number 8

Patient satisfaction and patient reported outcomes (PROMS) following HDR brachytherapy for prostate cancer at the Sussex Cancer Centre 

Nikapota AD, Cowtan F, Johns A, Appleyard S, Robinson AJ 
Sussex Cancer Centre, Royal Sussex County Hospital, United Kingdom 

Introduction: The prostate brachytherapy service at the Sussex Cancer Centre commenced in March 2014. To date 180 patients (pts) have received treatment, mostly as a boost in combination with external beam radiotherapy. Since commencing treatment as part of our quality assurance, service evaluation and to detect and respond to pts symptoms/poor QOL we have been prospectively collecting PROMS on all patients at 6 weeks, and annually from completion of radiation.

Methods: Here we present the data on the first 109 patients treated with a minimum of 24 months follow up. PROMs was assessed using a customised outcome form collecting validated symptom and QOL PROM items.

Results: Patient characteristics: median age 65 (range 51-79), 95% of pts had NCCN high risk disease. With a median follow up 41 months (range 25 – 60 months) biochemical/clinical relapse free survival is 97%. PROMS data is available for 100 pts. Overall satisfaction with treatment received – 93% (93/100) of patients satisfied/extremely satisfied. Ability to enjoy life: 81% good/v good; 18% fair. Ability to perform usual activities: 84% good/very good.

Conclusion: The use of PROMS should be routine in clinical practice to evaluate patient distress and symptomatology, but is still predominantly only collected in the clinical research setting. In our population we have demonstrated that the routine collection of PROMS is feasible with a high response rate to the questionnaire. We have demonstrated a high level of patient satisfaction and functional ability in an unselected group of patients treated with prostate brachytherapy. Early biochemical outcomes are excellent in this high risk population and consistent with published data.